Loading...

Cell-Vive™ GMP Recombinant Human IL-13 (carrier-free)

Pricing & Availability
Other Names
ALRH, BHR1, P600, IL-13, MGC116786, MGC116788, MGC116789, IL13
Ave. Rating
Submit a Review
Product Citations
publications
CV_GMP_RECOM_Human_IL-13_CF_082823
GMP recombinant human IL-13 induces the proliferation of human TF-1 cells in a dose-dependent manner. The ED50 for this effect is 0.5 – 3.0 ng/mL.
  • CV_GMP_RECOM_Human_IL-13_CF_082823
    GMP recombinant human IL-13 induces the proliferation of human TF-1 cells in a dose-dependent manner. The ED50 for this effect is 0.5 – 3.0 ng/mL.
Cat # Size Price Quantity Check Availability Save
571116 100 µg 1840€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
571114 25 µg 743€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Initially cloned from cDNA libraries of activated T cells, human IL-13 is an immunoregulatory cytokine produced by Th2 type helper T cells in response to signaling through the T cell antigen receptor and by mast cells and basophils upon cross-linkage of the high-affinity receptor for immunoglobulin E (IgE). IL 13 is a key mediator in the pathogenesis of allergic inflammation sharing many functional properties with IL-4 including the alpha subunit of the IL-4 receptor (IL-4Rα). IL-13 mediates its effects by interacting with a complex receptor system comprised of IL-4Rα and two IL-13 binding proteins, IL-13Rα1 and IL-13Rα2. Ligation of the IL-13 receptor complex results in signaling via the insulin receptor substrate (IRS)-1 and 2 and STAT-6 pathways. IL-13 has been implicated in airway hypersensitivity, mucus hypersecretion, inflammatory bowel disease, and parasitic nematode expulsion. In vitro studies suggest IL-13 decreases SARS-CoV-2 entry to bronchial epithelial cells.

Product Details
Quality Statement

BioLegend Cell-Vive™ GMP Recombinant proteins are manufactured and tested in accordance with USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Ph. Eur. Chapter 5.2.12 in a dedicated GMP facility compliant with ISO 13485:2016. Specifications and processes include:

  • Low endotoxin level (≤0.1 EU/μg)
  • Purity (≥ 95% or higher)
  • Bioburden testing
  • Mycoplasma testing
  • Batch-to-batch consistency
  • Vendor qualification
  • Raw material traceability and documentation
  • Documented procedures and employee training
  • Equipment maintenance and monitoring records
  • Lot-specific certificates of analysis
  • Quality audits per ISO 13485:2016
  • QA review of released products
Technical Data Sheet (pdf)

Product Details

Source
Human IL-13, amino acid (Gly21-Asn132) (Accession: # X69079) was expressed in E.coli.
Molecular Mass
The 112 amino acid recombinant protein has a predicted molecular mass of 12.3 kD. The DTT-reduced and non-reduced protein migrate at approximately 9 kD by SDS-PAGE. The N-terminal amino acid is Gly.
N-terminal
Sequence Analysis
Gly-Pro-Val-Pro-Pro-Ser-Thr-Ala-Leu-Arg
Purity
> 95%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.1 µm filtered protein solution is in 10 mM NaH2PO4, 150 mM NaCl, pH 7.2
Endotoxin Level
Less than or equal to 0.1 EU per μg protein as determined by the LAL method
Residual Host Cell Protein Content
≤0.500 ng/μg by ELISA
Concentration
25 µg and 100 µg sizes are bottled at 0.5 mg/mL
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin the vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week or stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
Human IL-13 induces proliferation of human TF-1 cells in a dose-dependent manner. The ED50 for this effect is 0.5 – 3.0 ng/mL. The specific activity of Cell Vive™ GMP Recombinant Human IL-13 (carrier-free) is ≥ 2.8 x 105 IU/mg when compared against the WHO International Standard for human IL-13 (NIBSC code: 94/622).
Application

Bioassay
Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Disclaimer

BioLegend Cell-Vive™ GMP Recombinant proteins are for research use only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

Antigen Details

Structure
Monomer
Ligand/Receptor
IL-4Rα, IL-13Rα1, and IL-13Rα2
Bioactivity
Human IL-13 induces the proliferation of TF-1 cells
Cell Sources
IL-13 is secreted by activated T cells, Th2 cells, basophils, mast cells, activated eosinophils and NK cells
Cell Targets
IL-13 receptors are expressed on human B cells, basophils, eosinophils, mast cells, endothelial cells, fibroblasts, monocytes, macrophages, respiratory epithelial cells, and smooth muscle cells
Antigen References
  1. McKenzie ANJ, et al. 1993. P Natl Acad Sci USA. 90:3735.
  2. Papasavvas E, et al. 2005. J. Immunol. 175:5532.
  3. Kelly-Wellch, et al. 2005. Science Signaling. 2005:293.
  4. Hershey GK. 2003. J Allergy Clin Immunol. 111:677.
  5. Harris J, et al. 2007. Immunity. 27:505.
  6. LaPorte SL, et al. 2008. Cell. 132:259.
  7. Jackson DJ, et al. 2020. J Allergy Clin Immunol. 146:203. e3.
  8. Bonser LR, et al. 2022. Am J Respir Cell Mol Biol. 66:391.
Regulation
IL-13 modulates human monocytes/macrophages and B cells. IL-13 induces an increase of MHC class II expression in human monocytes/macrophages, and direct inhibition of inflammatory cytokines such as TNF-α and IL-1β
Gene ID
3596 View all products for this Gene ID
UniProt
View information about IL-13 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 05.28.2025

For Research Use Only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account